Anisomycin prevents OGD-induced necroptosis by regulating the E3 ligase CHIP
- Sci Rep. 2018 Apr 23;8(1):6379. doi: 10.1038/s41598-018-24414-y.
- 1. Department of Neurology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou University, Zhengzhou, 450000, Henan, China.
- 2. The Institute of Clinical Medicine, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
- 3. McAllister Heart Institute, Chapel Hill, NC, 27514, USA.
- 4. Department of Cardiology, The University of North Carolina at Chapel Hill, Chapel Hill, NC, 27514, USA.
- 5. Department of Neurology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou University, Zhengzhou, 450000, Henan, China. [email protected].
- 6. Department of Neurology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou University, Zhengzhou, 450000, Henan, China. [email protected].
Necroptosis is an essential pathophysiological process in cerebral ischemia-related diseases. Therefore, targeting Necroptosis may prevent cell death and provide a much-needed therapy. Ansiomycin is an inhibitor of protein synthesis which can also activate c-Jun N-terminal kinases. The present study demonstrated that anisomycin attenuated Necroptosis by upregulating CHIP (carboxyl terminus of Hsc70-interacting protein) leading to the reduced levels of receptor-interacting protein kinase 1 (RIPK1) and receptor-interacting protein kinase 3 (RIPK3) proteins in two in vitro models of cerebral ischemia. Further exploration in this research revealed that losing neither the co-chaperone nor the ubiquitin E3 Ligase function of CHIP could abolish its ability to reduce Necroptosis. Collectively, this study identifies a novel means of preventing Necroptosis in two in vitro models of cerebral ischemia injury through activating the expression of CHIP, and it may provide a potential target for the further study of the disease.
-
Cat. No.Product NameDescriptionTargetResearch Area
-
Research Areas: Cancer
-